Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evaxion Biotech ( (EVAX) ) has issued an announcement.
On February 5, 2026, Evaxion Biotech’s board granted 6,544,725 warrants to directors, management and employees, with most vesting monthly from January 1, 2026, and a portion fully vested at grant, at an exercise price set in USD and converted to DKK with a floor of DKK 0.25 per share. Following this issuance, the company amended its Articles of Association and left capacity for additional warrants corresponding to a nominal DKK 7,482,257 in ordinary shares.
On February 16, 2026, the board approved a further 2,500,000 warrants to board members, management, staff and advisers, vesting monthly from November 1, 2025, at a higher USD-based exercise price subject to the same DKK 0.25 floor. After this second grant and related amendments to the Articles, Evaxion retained authority to issue more warrants for up to a nominal DKK 6,857,257 in shares, underscoring its continued reliance on equity-based incentives and potential future dilution for existing shareholders.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is held back primarily by weak financial fundamentals (ongoing losses, negative free cash flow, and balance sheet instability) and bearish technicals. Offsetting these, the latest earnings call was notably positive due to the MSD deal extending runway and strong EVX-01 clinical updates, while valuation support is limited given the negative P/E and no dividend.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion Biotech A/S, based in Hoersholm, Denmark, is a biotechnology company that develops advanced software to enable the creation of novel immunotherapies and vaccines. The company operates under the names Evaxion A/S, Evaxion Biotech A/S and NovVac A/S, and its shares are registered as non-negotiable instruments recorded by Computershare A/S.
Average Trading Volume: 77,271
Technical Sentiment Signal: Strong Sell
Current Market Cap: $21.92M
Find detailed analytics on EVAX stock on TipRanks’ Stock Analysis page.